media – Page 12 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

16 billion yuan! Novartis “runs” to enter the market

Recently, the molecular glue star company Monte Rosa Therapeutics announced that it has reached a global exclusive development and commercialization license agreement with Novartis to advance the development of molecular glue protein degraders targeting VAV1, including the research therapy MRT-6160. Under the terms of the agreement, Novartis agreed to pay Monte Rosa an advance payment of US$150 million. In addition, Monte Rosa is eligible to receive up to US$2.1 billion in development, regulatory and sales milestone payments (US$2.25 billion is approximately RMB 16 billion). Monte Rosa Therapeutics is headquartered in Boston, USA. The company was founded in 2018 and is a biotechnology company focusing on the development of molecular glue drugs. Its core technology platform is the QuEEN platform, which is mainly dedicated to the discovery and development of molecular glue drugs. Under the terms of the agreement, Monte Rosa will continue to be responsible for completing the ongoing Phase ...
- Source: drugdu
- 41
- November 4, 2024
Domestic PD-L1 was approved in the UK for the first time

CStone Pharmaceuticals announced today (October 31) that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved sugemalimab combined with platinum-containing chemotherapy for patients without EGFR sensitive mutations, or without ALK, ROS1, First-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with RET genomic tumor variants. This is the second marketing authorization application approval for sugalimab in overseas markets, following the approval by the European Commission. The approval was mainly based on the results of a multi-center, randomized, double-blind Phase III clinical study – GEMSTONE-302. Sugemalimab combined with chemotherapy can significantly extend the progression-free survival and overall survival of patients with newly treated metastatic NSCLC compared with placebo combined with chemotherapy. The research data has been published in The Lancet Oncology and Nature Cancer, and has been presented in oral and poster presentations at many international academic conferences. CStone Pharmaceuticals has reached a strategic cooperation with ...
- Source: drugdu
- 43
- November 4, 2024
Aimei Vaccine’s 13-Valent Conjugate Pneumococcal Vaccine Obtains Production License and Market Registration Submitted

On November 1, Aimei Vaccine announced that it has submitted a drug market registration application for its self-developed 13-valent conjugate pneumococcal vaccine to the National Medical Products Administration. The results from a completed Phase III clinical study show that Aimei’s 13-valent conjugate pneumococcal vaccine has demonstrated good immunogenicity and safety, meeting the clinical preset objectives. Aimei’s wholly-owned subsidiary, Aimei Biotechnology Co., Ltd., has obtained the corresponding drug production license for this product. The 13-valent conjugate pneumococcal vaccine has been referred to as the “king of global vaccines” and has been the world’s top-selling vaccine for ten consecutive years. Pfizer’s 13-valent conjugate pneumococcal vaccine (Prevnar 13®) is the best-selling vaccine globally and has frequently ranked among the top ten best-selling drugs worldwide. According to Pfizer’s 2023 annual report, global sales of Pfizer’s pneumococcal conjugate vaccine were approximately $6.44 billion in 2023. Over the years, the global sales of the 13-valent conjugate ...
- Source: drugdu
- 40
- November 4, 2024
Lizhong Group Reports Net Profit of 1.673 Billion Yuan in First Three Quarters, Revenue Declines for Five Consecutive Quarters

China Net Finance, November 1 – In the context of an expanding centralized procurement and a cool market for innovative drugs, Lizhong Group has still managed to maintain profit growth. The third-quarter report shows that the company achieved a net profit of 500 million yuan in a single quarter, a year-on-year increase of 7.45%. For the first three quarters, the cumulative net profit attributable to shareholders reached 1.673 billion yuan, which represents a year-on-year growth of 4.44%. The net profit after eliminating non-recurring gains and losses was approximately 1.631 billion yuan, up by 3.51%. In contrast to profit growth, Lizhong Group’s revenue has shown a downward trend. In the first three quarters, the company reported approximately 9.082 billion yuan in operating revenue, a year-on-year decline of 5.94%. From a quarterly perspective, Lizhong Group’s revenue has been declining for five consecutive quarters, with the first three quarters of this year reporting ...
- Source: drugdu
- 39
- November 4, 2024
Is the turning point of “Cosmic Pharmaceutical Factory” coming?

In 2022, Pfizer’s annual revenue exceeded $100 billion, making it the world’s largest pharmaceutical company in terms of revenue. However, as the COVID-19 pandemic quickly receded, revenue fell by 41% in 2023, and revenue ranking also dropped from first to fourth. Recently, the well-known radical investment institution Starboard Value invested $1 billion in Pfizer. What changes will this bring to this pharmaceutical giant? In 1849, Charles Pfizer and Charles Erhart founded Pfizer in New York, initially focusing on the production of chemical products. During World War II, Pfizer successfully mass-produced penicillin and launched oxytetracycline, officially entering the pharmaceutical industry. Since then, Pfizer has continued to expand through research and development and mergers and acquisitions, launched blockbuster drugs such as Norvasc and Viagra, and gradually became a leading global pharmaceutical company. Since the 21st century, Pfizer has topped the list of the top 50 pharmaceutical companies in the world (Pharm Exec ...
- Source: drugdu
- 63
- November 2, 2024
It is better to look at the long-term situation

October is coming to an end, and the third quarter “exam” of the innovative drug industry will also come to an end. From the surface, although the entire industry is still turbulent, new drug research and development is crowded with “involution”, commercialization challenges are numerous, and the capital winter is still spreading, but from the performance point of view, the situation does not seem to be as bad as imagined. On the one hand, as the product strength and commercialization capabilities of leading innovative pharmaceutical companies are constantly confirmed, their revenue continues to grow at a high rate and their profitability is enhanced; on the other hand, more and more pharmaceutical companies have also achieved phased results in cost control in reducing costs and increasing efficiency. The resonance of the two major factors has further expanded the “loss reduction” camp. Various signs indicate that in the cold winter after the ...
- Source: drugdu
- 53
- November 2, 2024
Domestic TCE polyclonal antibodies are “surging”

MNCs are hunting for domestic molecules and have already involved the field of TCE polyclonal antibodies. On October 29, GlaxoSmithKline announced the acquisition of Enmu Bio’s CD19 and CD20 targeted T cell engager CMG1A46, including a $300 million advance payment and $550 million in potential milestone payments. Not long ago in August, Merck also bought Tongrun Bio’s CD3xCD19 bispecific antibody CN201 with a down payment of $700 million and a milestone payment of $600 million. The direction of the giants is also relatively consistent: betting on the autoimmune market. At present, the core “battlefield” of TCE polyclonal antibodies is tumors. TCE polyclonal antibodies are relatively special. One end (or two ends) is connected to TAA (tumor-associated antigen) to locate tumor cells, and the other end is connected to the CD3 epitope of T cells to activate T cells and exert the tumor-killing effect of T cells. In the field of ...
- Source: drugdu
- 53
- November 2, 2024
Medici Globalization Strategy Accelerates, Overseas Business Reaches New Heights

On the evening of October 30, Medici released its Q3 2024 report. In the third quarter, the company achieved operating revenue of 280 million yuan, a year-on-year decrease of 9.83%, and a net profit loss attributable to shareholders of approximately 58.44 million yuan. The company attributed this primarily to changes in the investment and financing environment for biomedicine during the reporting period, intensified industry competition, declining order prices, delays in executing some orders, and a decrease in gross profit margins. Domestic and international laboratory progress is promising, deepening the global strategic layout. As a pioneer of China’s Contract Research Organizations (CRO), Medici has maintained a forward-looking approach since its inception, adhering to a dual-market development strategy that encompasses both domestic and international markets. Its overseas operations span many regions, including the United States, Europe, Japan, and South Korea, and the company has established deep cooperative relationships with internationally renowned pharmaceutical ...
- Source: drugdu
- 52
- November 2, 2024
Ensuring patients’ peace of mind through the stable operation of medical insurance institutions and enterprises – the medical insurance department is intensifying efforts to introduce incremental policies to serve and safeguard the overall development

Since the beginning of this year, the medical insurance department has firmly established the development concept centered on the people, adhered to the general tone of seeking progress while maintaining stability, grasped the key points, took the initiative, effectively implemented existing policies, strengthened the introduction of incremental policies, effectively grasped the bottom line of people’s livelihood, and served and guaranteed the overall macroeconomic development. Ensure patients can seek medical treatment with peace of mind and continue to promote cost reduction and efficiency improvement in medication consumption From January to September, medical insurance settled 6.916 billion people, a year-on-year increase of 19.3%, including 4.898 billion outpatient visits, an increase of 25% compared to the same period in 2023, effectively ensuring the demand for outpatient medical treatment. Deepen the reform of employee medical insurance outpatient mutual assistance guarantee, expand the scope of personnel and fund use in personal account mutual assistance, and ...
- Source: drugdu
- 55
- November 2, 2024
The first patient enrolled in the Phase III clinical trial of first-line treatment for biliary tract tumors using the head to head valumab regimen and the Ivo Western regimen

Recently, Kangfang Biotechnology (9926. HK) announced the completion of the first patient enrollment in a randomized, controlled, multicenter, registered Phase III clinical trial (HARMONI-GI-01/AK112-309) of its independently developed PD-1/VEGF bispecific antibody combination regimen with Ivexil and a comparison with Valiumab (PD-L1) combination regimen for first-line treatment of advanced biliary malignancies (BTC). Research on AK112-309 The HARMONI-GI-01/AK112-309 study was conducted by renowned domestic liver and gallbladder tumor experts, Professor Zhou Jian from Zhongshan Hospital affiliated with Fudan University and Professor Zheng Tongsen from Harbin Medical University Cancer Hospital, as co principal investigators. The endpoint of the study was overall survival (OS). The HARMONI-GI-01/AK112-309 study is the sixth registered phase III clinical trial conducted by Ecovaci, using PD-1/L1 monoclonal antibodies as control drugs. It reflects the company’s determination and confidence in iterating the current tumor immunotherapy landscape and establishing better global cancer standard treatments. It also demonstrates the ability of Kangfang Biotech ...
- Source: drugdu
- 46
- November 2, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.